Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors
Currently, serum chromogranin A is a well-established biomarker for pancreatic neuroendocrine tumors; however, other pancreatic diseases, oral use of a proton pump inhibitor and renal impairment can affect chromogranin A. Meanwhile, chromogranin B, belonging to the same granin family as chromogranin...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of clinical oncology 2017-06, Vol.47 (6), p.520-528 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 528 |
|---|---|
| container_issue | 6 |
| container_start_page | 520 |
| container_title | Japanese journal of clinical oncology |
| container_volume | 47 |
| creator | Miki, Masami Ito, Tetsuhide Hijioka, Masayuki Lee, Lingaku Yasunaga, Kohei Ueda, Keijiro Fujiyama, Takashi Tachibana, Yuichi Kawabe, Ken Jensen, Robert T Ogawa, Yoshihiro |
| description | Currently, serum chromogranin A is a well-established biomarker for pancreatic neuroendocrine tumors; however, other pancreatic diseases, oral use of a proton pump inhibitor and renal impairment can affect chromogranin A. Meanwhile, chromogranin B, belonging to the same granin family as chromogranin A, is not fully examined in these conditions. The present study aimed to evaluate the utility of chromogranin B as a pancreatic neuroendocrine tumor biomarker.
Serum chromogranin B levels were determined by radioimmunoassay and serum chromogranin A levels by enzyme-linked immunosorbent assay in pancreatic neuroendocrine tumor (n = 91) and other pancreatic conditions, and in healthy people (n = 104), to assess the relationships with clinical features.
The diagnostic ability of chromogranin B was as good as chromogranin A. The area under the curve was 0.79 for chromogranin B (sensitivity/specificity: 72%/77%), and 0.78 for chromogranin A (sensitivity/specificity: 79%/64%). Chromogranin B was not affected by proton pump inhibitor use and age, which affected chromogranin A. The number of cases without liver metastases was larger in pancreatic neuroendocrine tumor patients with positive chromogranin B and negative chromogranin A. Though chromogranin A significantly elevated cases with proton pump inhibitor treatment and had positive correlation with age, chromogranin B did not have the tendencies. However, both chromogranin B and chromogranin A elevated in the case with renal impairment. In addition, the logistic regression analysis showed that chromogranin B was superior to chromogranin A in differentiation of pancreatic neuroendocrine tumor from other pancreatic diseases.
Compared with chromogranin A, chromogranin B may be more useful during proton pump inhibitor treatment and can detect tumors without liver metastases. In addition, chromogranin B may be an excellent biomarker when differentiation of pancreatic neuroendocrine tumor from other pancreatic diseases is required. |
| doi_str_mv | 10.1093/jjco/hyx032 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6283109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28334992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-56d86a2f5892ee2d8bb7a82eee4d4d4507f5ccd202deea6f8d3e5f0118ca99283</originalsourceid><addsrcrecordid>eNpVUTtPwzAQthCIlsLEjryjUD-S1FmQSsVTlVjoHDn2pXFp4shOgW78dFwFKqob7vTd990ToUtKbijJ-Hi1UnZcbb8IZ0doSOM0iXjK6DEaEp6KiAlKB-jM-xUhJBHx5BQNmOA8zjI2RN-LzqxNt8W2xKpytrZLJxvT4DusbN1KBxp_mq46TE6x9FjiwthaundwOGAvspUNeMCt7Aw0ne91AVQOAqRwAxtnodFWOdMA7ja1df4cnZRy7eHi14_Q4uH-bfYUzV8fn2fTeaRikXVRkmqRSlYmImMATIuimEgRQoh1sIRMykQpzQjTADItheaQlIRSoWRYVPARuu3rtpuiBq3ChE6u89aZsMI2t9Lkh5nGVPnSfuRpEO_uPELXfQHlrPcOyr2WknxHyHePyPtHBPbV_3Z77t_l-Q9hHosL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Miki, Masami ; Ito, Tetsuhide ; Hijioka, Masayuki ; Lee, Lingaku ; Yasunaga, Kohei ; Ueda, Keijiro ; Fujiyama, Takashi ; Tachibana, Yuichi ; Kawabe, Ken ; Jensen, Robert T ; Ogawa, Yoshihiro</creator><creatorcontrib>Miki, Masami ; Ito, Tetsuhide ; Hijioka, Masayuki ; Lee, Lingaku ; Yasunaga, Kohei ; Ueda, Keijiro ; Fujiyama, Takashi ; Tachibana, Yuichi ; Kawabe, Ken ; Jensen, Robert T ; Ogawa, Yoshihiro</creatorcontrib><description>Currently, serum chromogranin A is a well-established biomarker for pancreatic neuroendocrine tumors; however, other pancreatic diseases, oral use of a proton pump inhibitor and renal impairment can affect chromogranin A. Meanwhile, chromogranin B, belonging to the same granin family as chromogranin A, is not fully examined in these conditions. The present study aimed to evaluate the utility of chromogranin B as a pancreatic neuroendocrine tumor biomarker.
Serum chromogranin B levels were determined by radioimmunoassay and serum chromogranin A levels by enzyme-linked immunosorbent assay in pancreatic neuroendocrine tumor (n = 91) and other pancreatic conditions, and in healthy people (n = 104), to assess the relationships with clinical features.
The diagnostic ability of chromogranin B was as good as chromogranin A. The area under the curve was 0.79 for chromogranin B (sensitivity/specificity: 72%/77%), and 0.78 for chromogranin A (sensitivity/specificity: 79%/64%). Chromogranin B was not affected by proton pump inhibitor use and age, which affected chromogranin A. The number of cases without liver metastases was larger in pancreatic neuroendocrine tumor patients with positive chromogranin B and negative chromogranin A. Though chromogranin A significantly elevated cases with proton pump inhibitor treatment and had positive correlation with age, chromogranin B did not have the tendencies. However, both chromogranin B and chromogranin A elevated in the case with renal impairment. In addition, the logistic regression analysis showed that chromogranin B was superior to chromogranin A in differentiation of pancreatic neuroendocrine tumor from other pancreatic diseases.
Compared with chromogranin A, chromogranin B may be more useful during proton pump inhibitor treatment and can detect tumors without liver metastases. In addition, chromogranin B may be an excellent biomarker when differentiation of pancreatic neuroendocrine tumor from other pancreatic diseases is required.</description><identifier>ISSN: 0368-2811</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyx032</identifier><identifier>PMID: 28334992</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Age Factors ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - blood ; Case-Control Studies ; Chromogranin A - blood ; Chromogranin B - blood ; Enzyme-Linked Immunosorbent Assay ; Female ; Gastrins - blood ; Humans ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Neuroendocrine Tumors - blood ; Neuroendocrine Tumors - drug therapy ; Original ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - drug therapy ; Proton Pump Inhibitors - therapeutic use ; ROC Curve ; Young Adult</subject><ispartof>Japanese journal of clinical oncology, 2017-06, Vol.47 (6), p.520-528</ispartof><rights>The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-56d86a2f5892ee2d8bb7a82eee4d4d4507f5ccd202deea6f8d3e5f0118ca99283</citedby><cites>FETCH-LOGICAL-c489t-56d86a2f5892ee2d8bb7a82eee4d4d4507f5ccd202deea6f8d3e5f0118ca99283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28334992$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miki, Masami</creatorcontrib><creatorcontrib>Ito, Tetsuhide</creatorcontrib><creatorcontrib>Hijioka, Masayuki</creatorcontrib><creatorcontrib>Lee, Lingaku</creatorcontrib><creatorcontrib>Yasunaga, Kohei</creatorcontrib><creatorcontrib>Ueda, Keijiro</creatorcontrib><creatorcontrib>Fujiyama, Takashi</creatorcontrib><creatorcontrib>Tachibana, Yuichi</creatorcontrib><creatorcontrib>Kawabe, Ken</creatorcontrib><creatorcontrib>Jensen, Robert T</creatorcontrib><creatorcontrib>Ogawa, Yoshihiro</creatorcontrib><title>Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>Currently, serum chromogranin A is a well-established biomarker for pancreatic neuroendocrine tumors; however, other pancreatic diseases, oral use of a proton pump inhibitor and renal impairment can affect chromogranin A. Meanwhile, chromogranin B, belonging to the same granin family as chromogranin A, is not fully examined in these conditions. The present study aimed to evaluate the utility of chromogranin B as a pancreatic neuroendocrine tumor biomarker.
Serum chromogranin B levels were determined by radioimmunoassay and serum chromogranin A levels by enzyme-linked immunosorbent assay in pancreatic neuroendocrine tumor (n = 91) and other pancreatic conditions, and in healthy people (n = 104), to assess the relationships with clinical features.
The diagnostic ability of chromogranin B was as good as chromogranin A. The area under the curve was 0.79 for chromogranin B (sensitivity/specificity: 72%/77%), and 0.78 for chromogranin A (sensitivity/specificity: 79%/64%). Chromogranin B was not affected by proton pump inhibitor use and age, which affected chromogranin A. The number of cases without liver metastases was larger in pancreatic neuroendocrine tumor patients with positive chromogranin B and negative chromogranin A. Though chromogranin A significantly elevated cases with proton pump inhibitor treatment and had positive correlation with age, chromogranin B did not have the tendencies. However, both chromogranin B and chromogranin A elevated in the case with renal impairment. In addition, the logistic regression analysis showed that chromogranin B was superior to chromogranin A in differentiation of pancreatic neuroendocrine tumor from other pancreatic diseases.
Compared with chromogranin A, chromogranin B may be more useful during proton pump inhibitor treatment and can detect tumors without liver metastases. In addition, chromogranin B may be an excellent biomarker when differentiation of pancreatic neuroendocrine tumor from other pancreatic diseases is required.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - blood</subject><subject>Case-Control Studies</subject><subject>Chromogranin A - blood</subject><subject>Chromogranin B - blood</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Gastrins - blood</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neuroendocrine Tumors - blood</subject><subject>Neuroendocrine Tumors - drug therapy</subject><subject>Original</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>ROC Curve</subject><subject>Young Adult</subject><issn>0368-2811</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUTtPwzAQthCIlsLEjryjUD-S1FmQSsVTlVjoHDn2pXFp4shOgW78dFwFKqob7vTd990ToUtKbijJ-Hi1UnZcbb8IZ0doSOM0iXjK6DEaEp6KiAlKB-jM-xUhJBHx5BQNmOA8zjI2RN-LzqxNt8W2xKpytrZLJxvT4DusbN1KBxp_mq46TE6x9FjiwthaundwOGAvspUNeMCt7Aw0ne91AVQOAqRwAxtnodFWOdMA7ja1df4cnZRy7eHi14_Q4uH-bfYUzV8fn2fTeaRikXVRkmqRSlYmImMATIuimEgRQoh1sIRMykQpzQjTADItheaQlIRSoWRYVPARuu3rtpuiBq3ChE6u89aZsMI2t9Lkh5nGVPnSfuRpEO_uPELXfQHlrPcOyr2WknxHyHePyPtHBPbV_3Z77t_l-Q9hHosL</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Miki, Masami</creator><creator>Ito, Tetsuhide</creator><creator>Hijioka, Masayuki</creator><creator>Lee, Lingaku</creator><creator>Yasunaga, Kohei</creator><creator>Ueda, Keijiro</creator><creator>Fujiyama, Takashi</creator><creator>Tachibana, Yuichi</creator><creator>Kawabe, Ken</creator><creator>Jensen, Robert T</creator><creator>Ogawa, Yoshihiro</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20170601</creationdate><title>Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors</title><author>Miki, Masami ; Ito, Tetsuhide ; Hijioka, Masayuki ; Lee, Lingaku ; Yasunaga, Kohei ; Ueda, Keijiro ; Fujiyama, Takashi ; Tachibana, Yuichi ; Kawabe, Ken ; Jensen, Robert T ; Ogawa, Yoshihiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-56d86a2f5892ee2d8bb7a82eee4d4d4507f5ccd202deea6f8d3e5f0118ca99283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - blood</topic><topic>Case-Control Studies</topic><topic>Chromogranin A - blood</topic><topic>Chromogranin B - blood</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Gastrins - blood</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neuroendocrine Tumors - blood</topic><topic>Neuroendocrine Tumors - drug therapy</topic><topic>Original</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>ROC Curve</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miki, Masami</creatorcontrib><creatorcontrib>Ito, Tetsuhide</creatorcontrib><creatorcontrib>Hijioka, Masayuki</creatorcontrib><creatorcontrib>Lee, Lingaku</creatorcontrib><creatorcontrib>Yasunaga, Kohei</creatorcontrib><creatorcontrib>Ueda, Keijiro</creatorcontrib><creatorcontrib>Fujiyama, Takashi</creatorcontrib><creatorcontrib>Tachibana, Yuichi</creatorcontrib><creatorcontrib>Kawabe, Ken</creatorcontrib><creatorcontrib>Jensen, Robert T</creatorcontrib><creatorcontrib>Ogawa, Yoshihiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miki, Masami</au><au>Ito, Tetsuhide</au><au>Hijioka, Masayuki</au><au>Lee, Lingaku</au><au>Yasunaga, Kohei</au><au>Ueda, Keijiro</au><au>Fujiyama, Takashi</au><au>Tachibana, Yuichi</au><au>Kawabe, Ken</au><au>Jensen, Robert T</au><au>Ogawa, Yoshihiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>47</volume><issue>6</issue><spage>520</spage><epage>528</epage><pages>520-528</pages><issn>0368-2811</issn><eissn>1465-3621</eissn><abstract>Currently, serum chromogranin A is a well-established biomarker for pancreatic neuroendocrine tumors; however, other pancreatic diseases, oral use of a proton pump inhibitor and renal impairment can affect chromogranin A. Meanwhile, chromogranin B, belonging to the same granin family as chromogranin A, is not fully examined in these conditions. The present study aimed to evaluate the utility of chromogranin B as a pancreatic neuroendocrine tumor biomarker.
Serum chromogranin B levels were determined by radioimmunoassay and serum chromogranin A levels by enzyme-linked immunosorbent assay in pancreatic neuroendocrine tumor (n = 91) and other pancreatic conditions, and in healthy people (n = 104), to assess the relationships with clinical features.
The diagnostic ability of chromogranin B was as good as chromogranin A. The area under the curve was 0.79 for chromogranin B (sensitivity/specificity: 72%/77%), and 0.78 for chromogranin A (sensitivity/specificity: 79%/64%). Chromogranin B was not affected by proton pump inhibitor use and age, which affected chromogranin A. The number of cases without liver metastases was larger in pancreatic neuroendocrine tumor patients with positive chromogranin B and negative chromogranin A. Though chromogranin A significantly elevated cases with proton pump inhibitor treatment and had positive correlation with age, chromogranin B did not have the tendencies. However, both chromogranin B and chromogranin A elevated in the case with renal impairment. In addition, the logistic regression analysis showed that chromogranin B was superior to chromogranin A in differentiation of pancreatic neuroendocrine tumor from other pancreatic diseases.
Compared with chromogranin A, chromogranin B may be more useful during proton pump inhibitor treatment and can detect tumors without liver metastases. In addition, chromogranin B may be an excellent biomarker when differentiation of pancreatic neuroendocrine tumor from other pancreatic diseases is required.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>28334992</pmid><doi>10.1093/jjco/hyx032</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0368-2811 |
| ispartof | Japanese journal of clinical oncology, 2017-06, Vol.47 (6), p.520-528 |
| issn | 0368-2811 1465-3621 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6283109 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Age Factors Aged Aged, 80 and over Biomarkers, Tumor - blood Case-Control Studies Chromogranin A - blood Chromogranin B - blood Enzyme-Linked Immunosorbent Assay Female Gastrins - blood Humans Logistic Models Male Middle Aged Multivariate Analysis Neuroendocrine Tumors - blood Neuroendocrine Tumors - drug therapy Original Pancreatic Neoplasms - blood Pancreatic Neoplasms - drug therapy Proton Pump Inhibitors - therapeutic use ROC Curve Young Adult |
| title | Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T10%3A43%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20chromogranin%20B%20compared%20with%20chromogranin%20A%20as%20a%20biomarker%20in%20Japanese%20patients%20with%20pancreatic%20neuroendocrine%20tumors&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Miki,%20Masami&rft.date=2017-06-01&rft.volume=47&rft.issue=6&rft.spage=520&rft.epage=528&rft.pages=520-528&rft.issn=0368-2811&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyx032&rft_dat=%3Cpubmed_cross%3E28334992%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28334992&rfr_iscdi=true |